RhythMedix Launches Next-Generation RhythmStar SL Cardiac Monitor

Mount Laurel, NJ — April 22, 2026 — RhythMedix, LLC, a Pharos Capital Group portfolio company and a nationwide cardiac monitoring company, has launched the next generation of its RhythmStar® SL cardiac monitoring wearable.

The third-generation design improves comfort, wearability, and patient adherence through a compact lead configuration, a waterproof IPX-6 rating, and longer battery life. Those gains matter clinically, because a monitor a patient is willing to keep wearing is a monitor that captures the event.

RhythmStar continues to differentiate through built-in cellular connectivity. ECG data transmits automatically to the cloud for prompt review across all monitoring modes, so a device never has to be mailed back before the data can be processed.

Paired with the company's proprietary Augmented Arrhythmia Intelligence™ (AAI), RhythmStar SL delivers precise arrhythmia detection by combining advanced algorithms with a multi-layered data review process.

"RhythmStar represents our commitment to delivering a better way to monitor, one that prioritizes both patient comfort and clinical performance. By combining a more wearable design with seamless data transmission and expert review, we're helping clinicians access the insights they need, when they need them," said Brian Pike, Chief Executive Officer of RhythMedix.

"RhythMedix is taking a truly visionary approach to cardiac monitoring by combining patient-friendly design with advanced technology and expert oversight, helping clinicians make more confident, timely decisions," said George Shaw, MD, Electrophysiologist at AHN Allegheny Health Network. "It's a meaningful step forward in how we deliver and manage cardiac care."

RhythMedix has monitored more than 2 million hearts to date.

About RhythMedix

Founded in 2013 and headquartered in Mount Laurel, New Jersey, RhythMedix is a fully integrated cardiac monitoring company providing end-to-end device manufacturing, software development, and around-the-clock US-based monitoring services. With no third-party dependence, RhythMedix delivers a seamless and secure remote cardiac monitoring experience for clinics, health systems, and patients nationwide. Pharos Capital Group acquired a majority stake in RhythMedix in 2023. To learn more, visit rhythmedix.com.

About Pharos Capital Group

Pharos Capital Group is a private healthcare investment firm committed to a patient-centric model that addresses the whole person. Founded by a physician, the company's mission includes building sustainable change in underserved areas: urban centers, rural communities, and tribal lands. We invest strategically by addressing the root causes of illness, expanding access to care, and improving the quality of care. We also aim to lower costs.

We believe healthy individuals, children, and families lead to flourishing communities, and ultimately, a flourishing nation. As such, a core part of our mission seeks to reduce healthcare inequities across the United States. Our portfolio companies have ranged from providing early detection and preventative cardiac screenings, to behavioral health supports, to chronic disease management, telehealth, home-based services for the elderly, compassionate end-of-life care, and services for homeless patients, among others. Pharos has provided services in all fifty states and on Native American tribal lands. As of September 30, 2025, Pharos had nearly $2 billion in assets raised to date.

Media Contact

Caroline Luz
Lambert by LLYC
(203) 570-6462
cluz@lambert.com

‍